Drugs / BBO-11818
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06917079 | Mar 2025 → Aug 2027 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBO-11818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06917079 ↗ |
| Action | Inhibit | “BBO-11818, a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor capable of targeting multiple KRAS mutants” PMID 41790032 ↗ Apr 2026 |
| Route | Oral | “Participants will receive assigned dose of BBO-11818 orally (PO)” NCT06917079 ↗ |
| Target | KRAS | “We discovered BBO-11818, a potent, selective, orally bioavailable noncovalent pan-KRAS inhibitor capable of targeting multiple KRAS mutants in both the inactive GDP-bound (OFF)...” PMID 41790032 ↗ Apr 2026 |